Burnstock, G; Krugel, U; Abbracchio, MP; Illes, P; (2011) Purinergic signalling: From normal behaviour to pathological brain function. PROG NEUROBIOL , 95 (2) 229 - 274. 10.1016/j.pneurobio.2011.08.006.
Full text not available from this repository.
Purinergic neurotransmission, involving release of ATP as an efferent neurotransmitter was first proposed in 1972. Later, ATP was recognised as a cotransmitter in peripheral nerves and more recently as a cotransmitter with glutamate, noradrenaline, GABA, acetylcholine and dopamine in the CNS. Both ATP, together with some of its enzymatic breakdown products (ADP and adenosine) and uracil nucleotides are now recognised to act via P2X ion channels and P1 and P2Y G protein-coupled receptors, which are widely expressed in the brain. They mediate both fast signalling in neurotransmission and neuromodulation and long-term (trophic) signalling in cell proliferation, differentiation and death. Purinergic signalling is prominent in neurone-glial cell interactions. In this review we discuss first the evidence implicating purinergic signalling in normal behaviour, including learning and memory, sleep and arousal, locomotor activity and exploration, feeding behaviour and mood and motivation. Then we turn to the involvement of P1 and P2 receptors in pathological brain function; firstly in trauma, ischemia and stroke, then in neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's, as well as multiple sclerosis and amyotrophic lateral sclerosis. Finally, the role of purinergic signalling in neuropsychiatric diseases (including schizophrenia), epilepsy, migraine, cognitive impairment and neuropathic pain will be considered. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.
|Title:||Purinergic signalling: From normal behaviour to pathological brain function|
|Keywords:||ATP, Nucleotidase, Purinoceptors, Brain, Learning, Sleep, Locomotion, Feeding, Mood, Trauma, Alzheimer's, Parkinson's, MS, ALS, Schizophrenia, Epilepsy, Cognition, Pain, ADENOSINE A(2A) RECEPTOR, CENTRAL-NERVOUS-SYSTEM, RAT HIPPOCAMPAL SLICES, AMYOTROPHIC-LATERAL-SCLEROSIS, LONG-TERM POTENTIATION, EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS, TEMPORAL-LOBE EPILEPSY, SPINAL-CORD-INJURY, METHYL-D-ASPARTATE, CHOLINERGIC BASAL FOREBRAIN|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Life Sciences > Biosciences (Division of)|
Archive Staff Only: edit this record